Loading...
Loading...
Contributors:
Dataset URI:
10.3389/fcimb.2026.1930268.s008IntroductionRoutine whole-genome sequencing (WGS) interpretation of Mycobacterium tuberculosis resistance focuses mainly on consensus-level mutations. Minority variants, quantified by allele frequency (AF), may indicate resistant subpopulations under drug pressure, but their association with treatment response in rifampicin-resistant or multidrug-resistant tuberculosis (RR/MDR-TB) remains unclear.MethodsWe retrospectively analysed RR/MDR-TB patients treated in Ningbo, China, from 2021 to 2025, integrating clinical, phenotypic, treatment, microbiological, and WGS data. Minority resistance-associated variants (RAVs) were defined as low-frequency variants matching WHO V2 mutation catalogue entries at AF ≥ 3%, with AF ≥ 5% defining the primary higher-frequency subset. Per-drug analyses excluded patients whose target genes had median depth ResultsWe analysed 229 RR/MDR-TB patients with linked WGS, treatment, and microbiological follow-up data. Fixed RAVs (WHO V2 catalogue-annotated) were carried by 220/229 patients (median 3, IQR 2–5). Minority RAVs at AF ≥ 3% were detected in 13 patients. Overall minority-RAV burden was not clearly associated with microbiological response after adjustment. The clearest signal involved treatment-matched AF ≥ 5% minority RAVs, whose carriers had a higher 6-month culture-positivity rate than non-carriers (4/7 [57.1%] vs 40/198 [20.2%]; adjusted odds ratio [aOR] 7.21, 95% CI 1.38–43.68; p = 0.020; q = 0.034), with a modest AUC increase from 0.675 to 0.695. Six-month positivity was highest among patients with both high fixed RAV burden and treatment-matched AF ≥ 5% minority RAVs (4/5 [80.0%] vs 15/106 [14.2%] in the low-burden non-carrier reference; Fisher’s exact p = 0.003).ConclusionMinority variants showed limited overall prognostic value, but higher-frequency treatment-matched variants provided a coherent signal for 6-month culture positivity when considered with fixed RAV burden. These exploratory findings support a cautious, treatment-aware review of selected minority variants and require external validation before clinical use.
Keyword(s):
Clinical Microbiology; culture conversion; minority variants; multidrug-resistant tuberculosis; rifampicin-resistant tuberculosis.
MeSH Term(s):
Grants and Funding:
No Grants or Funding Data Available
Associated Publication(s):
Supplementary Data:
No Supplementary Data Available
Related Dataset(s):
No Related Dataset Data Available
The National Library of Medicine (NLM) provides information about biomedical datasets. Inclusion on an NLM Web page does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: NLM Web Policies (nih.gov)